Shares of Neurometrix Inc (NASDAQ:NURO) have been given an average broker rating score of 3.00 (Hold) from the one brokers that cover the company, Zacks Investment Research reports. One investment analyst has rated the stock with a hold recommendation.
Zacks has also assigned Neurometrix an industry rank of 90 out of 257 based on the ratings given to related companies.
Separately, Zacks Investment Research lowered Neurometrix from a “buy” rating to a “hold” rating in a research note on Thursday, September 27th.
Neurometrix (NASDAQ:NURO) last posted its quarterly earnings data on Wednesday, October 17th. The medical device company reported $0.15 EPS for the quarter, topping the Zacks’ consensus estimate of ($0.19) by $0.34. Neurometrix had a negative return on equity of 0.90% and a negative net margin of 0.37%. The firm had revenue of $3.67 million for the quarter. On average, research analysts expect that Neurometrix will post 0.02 EPS for the current year.
Neurometrix Company Profile
NeuroMetrix, Inc, a healthcare company, develops and markets products for the detection, diagnosis, and monitoring of peripheral nerve and spinal cord disorders. The company develops wearable neuro-stimulation therapeutic devices and point-of-care neuropathy diagnostic tests to address chronic health conditions, including chronic pain, sleep disorders, and diabetes.
See Also: Inflation
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Neurometrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurometrix and related companies with MarketBeat.com's FREE daily email newsletter.